Literature DB >> 8738611

Transgenic mouse models of breast cancer.

L T Amundadottir1, G Merlino, R B Dickson.   

Abstract

Although valuable initial information can be gathered about transformation from in vitro studies, human cancer occurs in the context of a complex interaction with its environment and must ultimately be studied in living animals. Transgenic animal models have been used to study breast transformation for a number of years and have yielded valuable information on the subject. In this paper, we will summarize results from our laboratories, and others, regarding the use of transgenic mice to study breast tumorigenesis. We will also suggest future directions for the use of transgenic models to understand, and hopefully, one day to cure the disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8738611     DOI: 10.1007/bf01806083

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  129 in total

1.  The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling.

Authors:  E J Lowenstein; R J Daly; A G Batzer; W Li; B Margolis; R Lammers; A Ullrich; E Y Skolnik; D Bar-Sagi; J Schlessinger
Journal:  Cell       Date:  1992-08-07       Impact factor: 41.582

2.  Neu receptor dimerization.

Authors:  M J Sternberg; W J Gullick
Journal:  Nature       Date:  1989-06-22       Impact factor: 49.962

3.  Oncogenic activation of p185neu stimulates tyrosine phosphorylation in vivo.

Authors:  D F Stern; M P Kamps; H Cao
Journal:  Mol Cell Biol       Date:  1988-09       Impact factor: 4.272

4.  Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas.

Authors:  C Escot; C Theillet; R Lidereau; F Spyratos; M H Champeme; J Gest; R Callahan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

5.  Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice.

Authors:  Y Matsui; S A Halter; J T Holt; B L Hogan; R J Coffey
Journal:  Cell       Date:  1990-06-15       Impact factor: 41.582

6.  BCL-1 participates in the 11q13 amplification found in breast cancer.

Authors:  C Theillet; J Adnane; P Szepetowski; M P Simon; P Jeanteur; D Birnbaum; P Gaudray
Journal:  Oncogene       Date:  1990-01       Impact factor: 9.867

7.  Identification and cloning of two overexpressed genes, U21B31/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas.

Authors:  E Schuuring; E Verhoeven; W J Mooi; R J Michalides
Journal:  Oncogene       Date:  1992-02       Impact factor: 9.867

8.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen.

Authors:  A L Schechter; D F Stern; L Vaidyanathan; S J Decker; J A Drebin; M I Greene; R A Weinberg
Journal:  Nature       Date:  1984 Dec 6-12       Impact factor: 49.962

9.  DNA amplification at 11q13.5-q14 in human breast cancer.

Authors:  P Szepetowski; V Ollendorff; J Grosgeorge; A Courseaux; D Birnbaum; C Theillet; P Gaudray
Journal:  Oncogene       Date:  1992-12       Impact factor: 9.867

10.  Cyclin E, a potential prognostic marker for breast cancer.

Authors:  K Keyomarsi; N O'Leary; G Molnar; E Lees; H J Fingert; A B Pardee
Journal:  Cancer Res       Date:  1994-01-15       Impact factor: 12.701

View more
  9 in total

Review 1.  EGF-related peptides and their receptors in mammary gland development.

Authors:  R P DiAugustine; R G Richards; J Sebastian
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-04       Impact factor: 2.673

2.  Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGFalpha transgenic rats.

Authors:  B R Davies; A M Platt-Higgins; G Schmidt; P S Rudland
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

3.  The coexistence of ERBB2, INT2, and CMYC oncogene amplifications and PTEN gene mutations in endometrial carcinoma.

Authors:  Bozena Konopka; Aneta Janiec-Jankowska; Zygmunt Paszko; Marian Goluda
Journal:  J Cancer Res Clin Oncol       Date:  2003-12-09       Impact factor: 4.553

Review 4.  Genetically engineered mouse models of mammary intraepithelial neoplasia.

Authors:  R D Cardiff; D Moghanaki; R A Jensen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

5.  Prolactin induces ERalpha-positive and ERalpha-negative mammary cancer in transgenic mice.

Authors:  Teresa A Rose-Hellekant; Lisa M Arendt; Matthew D Schroeder; Kennedy Gilchrist; Eric P Sandgren; Linda A Schuler
Journal:  Oncogene       Date:  2003-07-24       Impact factor: 9.867

Review 6.  Animal models of breast cancer: their diversity and role in biomedical research.

Authors:  R Clarke
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

7.  Expression of a truncated Brca1 protein delays lactational mammary development in transgenic mice.

Authors:  Melissa A Brown; Hans Nicolai; Kathy Howe; Toyomasa Katagiri; El-Nasir Lalani; Kaylene J Simpson; Nathan W Manning; Andrew Deans; Phil Chen; Kum Kum Khanna; Mas Rina Wati; Beatrice L Griffiths; Chun-Fang Xu; Gordon W H Stamp; Ellen Solomon
Journal:  Transgenic Res       Date:  2002-10       Impact factor: 2.788

8.  The cytoplasmic domain of MUC1 induces hyperplasia in the mammary gland and correlates with nuclear accumulation of β-catenin.

Authors:  Yuan Li; Haiying Yi; Yixin Yao; Xiaodong Liao; Yiqun Xie; Jie Yang; Zheng Yan; Long Wang; Shunyuan Lu; Ying Kuang; Mingmin Gu; Jian Fei; Zhugang Wang; Lei Huang
Journal:  PLoS One       Date:  2011-04-20       Impact factor: 3.240

9.  Wnt signaling activation and mammary gland hyperplasia in MMTV-LRP6 transgenic mice: implication for breast cancer tumorigenesis.

Authors:  J Zhang; Y Li; Q Liu; W Lu; G Bu
Journal:  Oncogene       Date:  2009-11-02       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.